"Vir Biotechnology concludes Eclipse 1 Phase III trial enrolment for CHD" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Duvakitug outperformed placebo at week 14 in endoscopic response and was well tolerated among patients with moderately to severely active Crohn’s disease, according to research presented at ACG Annual ...

With Phase 6 nearing 90% allocation, Mutuum Finance (MUTM) has reached a pivotal point in its roadmap. The completion of Phase 1 and ongoing success of Phase 2 reflect strong execution, while the ...

Vast Space . SpaceX successfully launched its Bandwagon-4 mission on Sunday, sending 18 satellites into low-Earth orbit using ...

The first patient has been dosed in the DESTINY-Lung06 phase 3 trial evaluating Enhertu plus pembrolizumab versus pembrolizumab, platinum-based ...

MRT-6160 inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly, ...

Mumbai: The much-awaited Metro Line 2, also known as the Yellow Line, is steadily inching closer to completion, promising a seamless link between Mumbai’s eastern and western suburbs. The 23.6-km ...

Mumbai: Work on Metro Line 2—also known as the Yellow Line—which will connect Mumbai’s eastern and western suburbs, is progressing steadily, according to Mumbai Metropolitan Region Development ...

Negotiators for Israel and Hamas have agreed to pause fighting in Gaza to release the remaining hostages in exchange for Palestinian prisoners, adopting parts of a ...

Prime Minister Narendra Modi on Wednesday inaugurated Phase 1 of the Navi Mumbai International Airport. Built at a cost of Rs 19,650 crore under a public-private partnership between Adani Airports and ...

AUSTIN (KXAN) — The Congress Avenue Urban Design Initiative (CAUDI) is preparing for the first construction phase to redesign Congress Avenue between Cesar Chavez and 7th Streets in downtown Austin.

-Clinical data to date supports a potentially transformational approach to treating autoimmune diseases with an off-the-shelf, one-time therapy- -As of the August 31, 2025 data cut-off date, all seven ...